A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation

Inclusion Criteria:

• Willing and able to comply with all scheduled visits, treatment plan, laboratorytests, lifestyle considerations (including contraception requirements), and otherstudy procedures

• Histologically confirmed advanced, recurrent, or metastatic solid tumor malignancywith any mutation of SMARCA4 by local testing that has either progressed on or isineligible for standard of care therapy

• Must have measurable or non-measurable (but evaluable) disease per RECIST v1.1

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Willing to provide either archival or fresh tumor tissue sample

• Adequate organ function (hematology, renal, and hepatic)

Exclusion Criteria:

• Participants with solid tumors with known concomitant SMARCA2 mutation or loss ofprotein expression

• Clinically significant or uncontrolled cardiac disease, uncontrolled electrolytedisorders, uncontrolled or symptomatic central nervous system (CNS) metastases orleptomeningeal disease

• History of other malignancy within 3 years except for adequately treated basal cellor squamous cell skin cancer, superficial bladder cancer, prostate intraepithelialneoplasm, prostate adenocarcinoma with Gleason score of 3+3 or less, carcinoma insitu of the cervix, or other non-invasive or indolent malignancies, or malignanciespreviously treated with curative intent and not on active therapy or expected torequire treatment or recurrence during the study

• Receipt of any targeted therapy directed against BRM/BRG1 (SMARCA2/SMARCA4).